2-溴-5-(2-硝基丙-1-烯基)呋喃 | 35950-37-9

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 芳基卤化物
• 中文名称: 2-溴-5-(2-硝基丙-1-烯基)呋喃
• 英文名称: 1-(5-bromo-2-furyl)-2-nitropropene
• 英文别名: 2-Bromo-5-(2-nitroprop-1-en-1-yl)furan；2-bromo-5-[(E)-2-nitroprop-1-enyl]furan
• CAS: 35950-37-9
• 化学式: C₇H₆BrNO₃
• 分子量: 232.034
• InChiKey: NTCSJAIZGNPUBU-SNAWJCMRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  59
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-溴-5-(2-硝基丙-1-烯基)呋喃 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 生成 1-(5-bromo-2-furyl)-2-aminopropane
  参考文献：
  名称：

  Heteroarylisopropylamines as MAO inhibitors

  摘要：

  The in vitro monoamine oxidase inhibitory (MAOI) activities of 11 heteroarylisopropylamines vis-a-vis MAO-A and MAO-B were described and interpreted in terms of possible interactions with the enzyme active site. Molecular dynamics simulations allowed a comparison between the most active MAO-A inhibitor of the series, the 1-(2-benzofuryl)-2-aminopropane, and the specific, analogous MAO-A substrate serotonin. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.04.045
• 作为产物：
  描述：

  5-溴-2-呋喃甲醛 、 硝基乙烷 在 溶剂黄146 、 正丁胺 作用下， 反应 2.0h， 以82%的产率得到2-溴-5-(2-硝基丙-1-烯基)呋喃
  参考文献：
  名称：

  Heteroarylisopropylamines as MAO inhibitors

  摘要：

  The in vitro monoamine oxidase inhibitory (MAOI) activities of 11 heteroarylisopropylamines vis-a-vis MAO-A and MAO-B were described and interpreted in terms of possible interactions with the enzyme active site. Molecular dynamics simulations allowed a comparison between the most active MAO-A inhibitor of the series, the 1-(2-benzofuryl)-2-aminopropane, and the specific, analogous MAO-A substrate serotonin. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.04.045

文献信息

• PHARMACEUTICAL COMPOSITIONS CONTAINING NITROVINYLFURAN DERIVATIVES FOR THE TREATMENT OF LEISHMANIASIS AND TRYPANOSOMIASIS
  申请人：CENTRO DE BIOACTIVOS QUIMICOS

  公开号：EP1941877B1

  公开（公告）日：2009-11-18
• Pharmaceutical Compositions Containing Nitrovinylfuran Derivatives for the Treatment of Leishmaniosis and Trypanosomosis
  申请人：Castanedo Cancio Nilo Ramon

  公开号：US20090042978A1

  公开（公告）日：2009-02-12

  The present invention describes the action of a new family of drugs against a number of Leishmania species and Trypanosona cruzi , for the treatment of cutaneous, mucocutaneous and visceral leishmaniosis as well as tripanosomosis. In vitro assays and studies conducted in animal models and in human patients demonstrated that the compounds had a higher activity compared to drugs in clinical use against Leishmania mexicana amazonensis, L. donovani infantum, L. braziliensis braziliensis and Trypanosoma cruzi. The pharmaceutical activity of compositions based on such family of compounds was evidenced and supports its human and veterinary application for the treatment of the above-mentioned diseases by using different administration routes.